Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Bioasis tweet on Twitter!!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(111)
•••
Comment by prophetoffactzon Jan 02, 2023 10:37am
110 Views
Post# 35199513

RE:Bioasis tweet on Twitter!!!

RE:Bioasis tweet on Twitter!!!In truth it reads,,,,:
"Happy New Year! As we head into 2023, we transfer 93% of our assets to our new colleagues and partners and keep 7% for ourselves."

Does 7% materially understate what BTI shareholders are getting? Aren't BTI shareholders also responsible for BTI's outstanding warrants, BTI's obligations to Cresense, BTI's obligations to Lind, and BTI's obligations to Ladenberg Thalmann for taking this deal on spec and arranging the financing, etc.?

Biodexa is also given potentially $20 million towards putting the company on a sound financial footing and towards key catalysts during a time when 25% of the industry has been trading below cash in recent months. What should they get?

Q-Sphera and Midatech's lead cancer drug have also been tested in humans; unlike xB3.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities